Search Results
Your search for where matches 5550 pages
Showing 1501 - 1550AACI Members Choose Robert Winn, MD, as Vice President/President-Elect, and Other New Leaders
Robert Winn, MD, Director of Virginia Commonwealth University (VCU) Massey Cancer Center, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Winn’s new position is effective...
Nationally Recognized Biostatistician Joins Rutgers to Focus on Cancer Research
The Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey have welcomed nationally recognized biostatistician Hao Liu, PhD. Dr. Liu will serve as Professor in the Department of Biostatistics and Epidemiology at Rutgers School of Public Health, Director of the Biostatistics...
Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as Professor of Urology, Director of Education, and Director of the Precision Prostatectomy...
From Istanbul to Orange County, an Oncologist’s Journey to a Leadership Role in Quality Care
Pelin Cinar, MD, MS, was born and reared in Istanbul, Turkey. “My father ran a small furniture business, and my mother was a homemaker. However, I had a distant cousin who was an obstetrician-gynecologist, but he did house calls and treated any number of health issues in the community. Early on, I ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bahrain
The Kingdom of Bahrain is a high-income island nation located in the Persian Gulf. The nation is an archipelago consisting of two separate groups of islands spanning 30 miles north to south, 10 miles east to west, and about 3.5 times the size of Washington, DC. Though situated in a region rich in ...
Lung Cancer Screening Rates Improved in 19 States Despite the COVID-19 Pandemic
A new population-based study showed that although national lung cancer screening rates decreased in some states, 19 states actually experienced significant improvements in screening rates despite the COVID-19 pandemic. Overall lung cancer screening rates remained low and unchanged, according to...
An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ashraf Zaghloul, MD, DrPH, Professor at the National Cancer Institute of Egypt and President of the Egyptian Society of Surgical Oncology. Dr. Zaghloul was born in 1956 in ...
Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML
Aspacytarabine, a cytarabine prodrug, was reported to be safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who were unfit for intensive induction chemotherapy, according to the results of a phase II study presented during the 2021 ASCO Annual Meeting.1 The...
Study Highlights Gaps in Mental Health and Chemical Dependency Care at U.S. Cancer Centers
Research published by Niazi et al in JNCCN—Journal of the National Comprehensive Cancer Network indicates a need to increase mental health and chemical dependency support capabilities at cancer centers across the United States. Previous studies have determined that people diagnosed with cancer...
Racial/Ethnic Disparities in Emergency Department Visits After Breast Cancer Surgery
Among women undergoing surgery for breast cancer, up to 13% will have a postoperative visit to an emergency department, according to recent research. A new study published by Falcone et al in Breast Cancer Research and Treatment discovered there is a greater likelihood that Hispanic and...
Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible for Some Patients With Liver Cancer
A combination of the kinase inhibitor cabozantinib and the immunotherapy nivolumab may make curative surgery possible for some patients with liver cancer who would generally not be considered candidates for surgery, according to research published by Ho et al in Nature Cancer. Rates of Resection...
Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers
In an Israeli single-institution prospective cohort study reported in The New England Journal of Medicine, Bergwerk et al identified breakthrough COVID-19 infections among 39 of 1,497 health-care workers fully vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine. As stated by the investigators:...
Expert Point of View: Giuseppe Curigliano, MD, PhD
Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the...
ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published by Kilian E. Salerno, MD, and colleagues in Practical Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft-tissue sarcomas. Recommendations outline optimal...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Weekly Outpatient Palliative Care Interventions Among Patients With Head and Neck Cancer
Over 90% of patients with head and neck cancer receiving curative-intent chemoradiation therapy found weekly palliative care visits to be a valuable addition to their treatment, a recent study published by Bauman et al in the Journal of Palliative Medicine found. Although palliative care is known...
ASCO Honors John V. Cox, DO, MBA, FACP, FASCO, With 2021 Joseph V. Simone Award
ASCO will recognize John V. Cox, DO, MBA, FACP, FASCO, a medical oncologist and professor at the University of Texas Southwestern, with the Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer. Dr. Cox will be presented with the award at the...
ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer
Ovarian cancer carries a heavy morbidity and mortality burden, particularly in settings and regions of the globe that feature significant limitations in health-care resources. Given that ovarian cancer is more lethal than breast cancer, clinicians in resource-limited areas require guidance on the...
Lorlatinib for Metastatic ALK-Positive NSCLC
On March 3, 2021, lorlatinib was granted regular approval for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ALK-positive tumors as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA simultaneously approved the Ventana ALK (D5F3) CDx Assay ...
Breast Cancer in 2030: Predictions From a Breast Cancer Luminary
According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by the use of artificial intelligence (AI) in many facets of care and by the approval of a wave of new ...
Fox Chase Cancer Center Welcomes Peter Abdelmessieh, DO, MSc
Fox Chase Cancer Center recently announced that Peter Abdelmessieh, DO, MSc, will be joining the staff of the Department of Bone Marrow Transplant and Cellular Therapies. Prior to joining Fox Chase, Dr. Abdelmessieh was at Christiana Care Health System in Delaware, where he performed a majority of ...
I’m Alive by Sheer Force of Will—and a Lot of Luck
From the moment I felt a searing pain go through my right breast, I had a premonition that something was very wrong. Although I couldn’t feel anything unusual when I did a breast self-exam, I made an appointment with my gynecologist for a more thorough clinical breast exam and a mammogram. Because...
The Compelling Story of Cystic Fibrosis and the Dawn of Precision Medicine
Woe to the child who tastes salty from a kiss on the brow” was a forbidding prophecy from Medieval Europe, presaging unknown disease. Today, we know that salty skin is a telltale sign of cystic fibrosis in children, a disease that eluded medical identification until 1938, when an American...
Canadian Oncologists Report Costly Delays in Their Drug Regulatory Process
Canada’s publicly funded health-care system has a complex drug approval and funding process. Due to multiple assessment steps and bureaucratic processes, newly developed cancer drugs can often experience long delays before oncologists may use them to treat their patients with cancer. Several...
UCSF Names Ajay Maker, MD, FACS, Chief of Surgical Oncology
Ajay Maker, MD, FACS, has been appointed Chief of the new Division of Surgical Oncology in the Department of Surgery and the Maurice Galante Distinguished Professor in Surgical Oncology at the University of California, San Francisco (UCSF). He will lead surgical oncology services—including breast,...
Bringing Palliative Care to Native American Patients With Cancer
Native Americans are among the most underserved minority populations in the United States and are disproportionately affected by cancer. They have the lowest survival rates for nearly all types of cancer of any minority population and much higher rates of certain types of cancer, including lung,...
Phase III GLOW Trial: Improved Outcomes With First-Line Ibrutinib Plus Venetoclax in Elderly Patients With CLL
Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior outcomes compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL), based on the primary analysis of the phase III GLOW trial presented during the European Hematology...
Bridging the Gender Gap in Oncology
Women account for a growing proportion of the oncology workforce. Multiple studies, however, show that women oncologists are underrepresented in leadership positions, may have significantly lower salaries than men, and may be subjected to discriminatory practices stimulated by a medical culture...
Role of PI3K Inhibition in Indolent Lymphomas
As reported by Fowler et al in the Journal of Clinical Oncology1—and summarized in this issue of The ASCO Post—the international phase IIb UNITY-NHL trial of 208 patients with marginal zone lymphoma (MZL; n = 69), follicular lymphoma (FL; n = 117), and small lymphocytic lymphoma (SLL; n = 22)...
Nomograms for Predicting Outcomes With LuPSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
In a retrospective study reported in The Lancet Oncology, Gafita et al developed nomograms for predicting overall survival and prostate-specific antigen (PSA) progression-free survival outcomes in men receiving lutetium-177–PSMA (LuPSMA) treatment for metastatic castration-resistant prostate...
Expert Point of View: Carol Aghajanian, MD
“The phase III ENGOT/GCIG study1 proved to be negative, with no advantage seen with the extension of bevacizumab treatment,” said the abstract’s invited discussant, Carol Aghajanian, MD, Chief of the Medical Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, New York. Dr....
Study Identifies MET Amplification as a Driver for Some Non–Small Cell Lung Cancers
A study published by D. Ross Camidge, MD, PhD, and colleagues in the Journal of Thoracic Oncology has helped to define MET amplification as a rare but potentially actionable driver for non–small cell lung cancer (NSCLC). Dr. Camidge said many of the major developments in the treatment of NSCLC have ...
Study Estimates Costs Associated With Metastatic Breast Cancer Treatment May Increase Substantially in the Coming Decade
A study from the UNC Center for Health Promotion and Disease Prevention (HPDP) estimates that annual costs associated with metastatic breast cancer treatment among women in the United States will total $152.4 billion in 2030—nearly two and a half times the estimate for 2015 costs—due to an increase ...
Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC
As reported in the Journal of Thoracic Oncology by Christian Rolfo, MD, PhD, and colleagues, the International Association for the Study of Lung Cancer (IASLC) has issued a consensus statement on the use of liquid biopsy in advanced non–small cell lung cancer (NSCLC). Select recommendations are...
FDA Approves Belumosudil for Chronic Graft-vs-Host Disease
On July 16, the U.S. Food and Drug Administration (FDA) approved belumosudil (Rezurock), a kinase inhibitor, for adult and pediatric patients aged 12 years and older with chronic graft-vs-host disease after failure of at least two prior lines of systemic therapy. KD025-213 Efficacy was evaluated in ...
Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination
In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...
Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer
More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. The diet, which is high in fat and low in carbohydrates, led to changes in the metabolism in the body and the...
DESTINY-Gastric01 Exploratory Biomarker Analysis Examines Efficacy of Trastuzumab Deruxtecan-nxki Among Patients With HER2-Positive and HER2-Low Gastric Cancer
Trastuzumab deruxtecan-nxki demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer, according to findings from a post hoc exploratory biomarker analysis presented by Kohei Shitara, MD, and colleagues at the ESMO World ...
Breast Cancer Expert Joseph A. Sparano, MD, FACP, to Join Mount Sinai Health System
Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and human immunodeficiency virus (HIV)-associated malignancies, Joseph A. Sparano, MD, FACP, as Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute...
Suresh S. Ramalingam, MD, Named New Executive Director at Winship Cancer Institute
Suresh S. Ramalingam, MD, has been named Executive Director of Winship Cancer Institute of Emory University. An internationally renowned thoracic oncologist and physician-scientist, Dr. Ramalingam has served as Winship’s Deputy Director since 2016. He began his new post on July 1. Dr. Ramalingam...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
ASCO Congratulates Chiquita Brooks-LaSure on Confirmation as CMS Administrator
Monica M. Bertagnolli, MD, FACS, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), issued the following statement. “The Association for Clinical Oncology congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services ...
Expert Point of View: Melinda Telli, MD
EA1131 study discussant, Melinda Telli, MD, Associate Professor of Medicine at Stanford University, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, commented: “At this point,1 capecitabine remains preferred as...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial
The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...
Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
Annual Report to the Nation: Continued Decline in Cancer Death Rate
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
